The monitoring visit report, explained.

What a monitoring visit report is, and why a monitor's evening write-up outlives the trial

One site visit, from the monitor's notes to an inspector's desk

1. The visitSite 114, October 1. The monitor reviews consent forms, source records, medicine and the site file, and fills in a checklist.
2. NotesDictated on the drive home, or typed that evening. Often all that exists for a few days.
3. The report is written and checked against everything elseLast report's open actions, the monitoring plan's rules, the study databases. Every sentence has to hold up against them. This step is the subject of this guide.
4. Review, decision, signatureThe trial manager fixes, returns or signs, and decides what escalates. The site gets a follow-up letter.
5. An inspector reads itSometimes years later, next to the site's own records. Whatever the report says that day is the evidence.

The site and dates in this example are fictional.

Four facts about monitoring reports that surprise newcomers

CRA, monitoring plan, open action, important deviation: the words to know

Fourteen terms are defined in the one-page summary.

Initiation, interim, close-out and remote: the monitoring visits that each leave a report

In shortE6(R3) lists site monitoring reports for selection, initiation, routine and close-out visits as essential records, with centralized monitoring reports alongside them. The interim visit, the routine one that repeats, is the report with a memory problem. How often it happens depends on risk, and the monitoring plan sets it.

E6(R3) uses the term broadly: a monitoring report covers monitoring at a site, in person or remotely, and centralized monitoring done from a desk with analytics. Appendix C keeps those reports among the trial's essential records.1 So a report joins the permanent file as soon as it exists, and nobody can quietly tidy it away later.

E6(R3) says the frequency of monitoring "should also be determined based on identified risks" and should change with what you learn.1 This approach is called risk-based monitoring: more attention goes where the risk is higher. Tufts' Center for the Study of Drug Development surveyed field CRAs on their 2024 experience and found three kinds of schedule in about equal shares: fixed 34.5%, adaptive 32.6% and workload-based 32.9%.5

A longer interval has a cost in this document. An action raised 12 weeks ago and one raised four weeks ago look alike in a table. A report has to show age as well as existence, and section 05 works through how.

The monitoring plan is the rule book a report is checked against

E6(R3) asks for a monitoring plan tailored to the risks of the trial, focused on what is critical to quality, and naming methods, tools and who does what.1 FDA's guidance adds that documentation should carry "sufficient detail to allow verification that the monitoring plan was followed".6 That sentence sets the real test for a report. An inspector holds it up against the plan, so a plan that says "review consent for all participants" and a report that says "consent reviewed" leave a question about how many, on which version, and what was done about the exceptions.

ICH E6(R3), 21 CFR 312 and EU Regulation 536/2014: who requires monitoring reports, and since when

In shortUS and EU law require monitoring and leave the report's shape to the sponsor. ICH E6(R3) is the shared text on what the report contains, and it took effect in the EU in July 2025. FDA's guidance fills in the detail. One text is still moving: FDA's draft on protocol deviations.

Four names recur below. ICH is the International Council for Harmonisation, which writes shared standards for regulators and industry. 21 CFR is Title 21 of the US Code of Federal Regulations, where FDA's rules sit. EMA is the European Medicines Agency, and MHRA is the UK's medicines regulator.

This guide covers the US, the EU and the UK. Other authorities have their own texts, and your counsel and quality group should read them for the countries you run in. None of this is legal advice.

What goes in a monitoring visit report: the four ICH elements, FDA's five and a typical template

In shortE6(R3) asks for four things: what was reviewed, significant findings, conclusions and actions, and follow-up including what earlier reports left unresolved. FDA adds the date, the people, and an owner and date for each action. Templates turn that into sections, twelve in this guide's example, written from different sources.

Section 3.11.4.6(a) of E6(R3) is one sentence: "Reports of monitoring activities should include a summary of what was reviewed, a description of significant findings, conclusions and actions required to resolve them and follow-up on their resolution including those not resolved in previous reports."1 Part (c) adds that when needed, the report "should describe findings requiring escalation for action and resolution", and that the sponsor's decisions and the resolution of those actions should be recorded.1

FDA's list is plainer and more mechanical. Documentation should generally include the date and the individuals conducting and participating, a summary of what was reviewed, a description of noncompliance, potential noncompliance, data irregularities or other deficiencies, and a description of actions, "including the person responsible for completing actions and the anticipated date of completion".6,3

The twelve sections of one interim monitoring visit report template

Forms differ between sponsors, because the protocol decides what a monitor has to look at. The table below shows one interim report, the twelve sections in this guide's fictional example, with the question each must answer and where the facts come from. Note how many come from somewhere other than the monitor's memory.

Rolling action items forward in an interim visit report: four fates, and how to count an action's age

In shortThe rule reaches back to earlier reports, so each open action needs a stated fate at every visit: closed before, closed at this visit, carried forward with its age, or missing. Age needs a fixed start and end date. No rule sets a limit, so a sponsor sets its own, usually in days and in visits.

Copying last visit's table into the new report repeats it and tells the reader nothing. The rule asks for follow-up on resolution, so the useful question for each action is what has happened to it as of this visit, and how you know. Writing those outcomes down is a small change to a template, and it answers the rule directly.

Counting an open action's age, worked through on a fridge excursion

The guide's fictional example: at Site 114 a fridge holding trial medicine reached 9.1 °C for 46 minutes on August 14, a temperature excursion. The monitor raised an action at the August 27 visit, due September 15, asking the site to assess it and confirm the affected kits of medicine were quarantined. The next visit was October 1. The monitor submitted his report that evening, and the trial manager reviewed it on October 7.

A report can state any of three ages, so long as the plan says which: from the event (54 days on October 7), from when the action was raised (41) or from the due date (22 days overdue). The count can end at the visit, at drafting or at review. A report where one action counts from the event and another from the visit cannot be defended, so pick one rule and write it in the plan.

How long an action can stay open before the plan says escalate

No rule gives a number. E6(R3) says actions in relation to deviations, errors or omissions "should be proportionate to their importance".1 So the threshold is a sponsor's decision, and it works better with two conditions: an age and a number of visits. Age alone misses the action that has survived two weekly visits. Visits alone miss the action at a site seen every 12 weeks, open for five months without crossing a second visit.

Protocol deviation or serious breach: three routes for one monitoring finding, and the clock on each

In shortMost deviations are recorded and counted. A subset is important, by criteria the sponsor sets for each trial, and those go to a person who decides, on the sponsor's own clock. A smaller set may be serious breaches, reportable within seven days in the EU and UK. The report is often where the first sorting happens, and a wrong word there can stall it.

Deviations are ordinary. Tufts found a mean of 75 deviations per Phase 2 protocol and 119 per Phase 3 protocol, across data from 187 protocols, involving nearly one third of patients enrolled.17 A monitor will find them at most visits, and the question is what each one is.

Sorting a finding: ordinary deviation, important deviation or suspected serious breach

The US has no notification with that name. Under 21 CFR 312.56(b) a sponsor who discovers noncompliance must promptly secure compliance or end the investigator's participation and notify FDA.12 E6(R3) 3.12.2 calls the top level "serious noncompliance" and asks for root cause analysis, corrective and preventive action, and notification where required.1

Why a "reminder" about a superseded consent form can hide an important deviation

In the fictional example, participant 114-019 signed version 3.0 of the consent form on September 9, though version 4.0 was approved by the ethics committee on August 22 and in use at the site from September 1. The monitor's draft says "the site was reminded to use the current version". That sentence is true and reads as closed. Under this trial's plan the event is an important deviation with a two-working-day escalation.

The classification depends on the plan: E6(R3) makes the criteria trial-specific.1 FDA's sponsor observation lists do include "ICFs not approved by IRB prior to use" and sites that "used unapproved ICFs", so an old version in a screening folder deserves a look.18,19 An ICF is an informed consent form, and an IRB is a US ethics committee. What a report must avoid is deciding by choice of verb. "Reminded" closes the matter without anyone having decided.

CTMS, EDC and IRT against the draft: the comparisons that find what a re-read cannot

In shortA monitoring report makes claims about numbers the monitor did not count: enrollment is in one system, medication and queries in a second, randomization and medicine in a third. All three move after the visit. Each claim can be compared with its source, and a difference is often harmless once someone has noticed it.

Three systems sit behind most reports. A clinical trial management system, CTMS, holds sites, visits and milestones. Electronic data capture, EDC, holds what the site entered for each participant, including medications and open queries, the questions sent to a site about an entry. Interactive response technology, IRT, randomizes participants and tracks the medicine. E6(R3) asks monitoring to check "the accuracy, completeness and consistency of the reported trial data against the source records and other trial-related records".1 A report that cites those numbers should meet the same standard.

Four sentences from a draft, each compared with its source

All four are from the guide's fictional sample. Participant numbers are study codes, and a report never carries a name.

Timing explains the first row. The monitor dictates on the evening of the visit from the site log as it stood that morning, and the log did not yet show a participant randomized the day before. Neither is wrong: the two records were true at different times. An inspector reading "22" next to "23" is untroubled if the sponsor noticed. A sponsor that did not notice has a different kind of problem.

Opinions about people read badly years later

The fictional draft says "The principal investigator seemed disengaged and the coordinator is doing most of the work." A trial manager will often have the same worry, and it may be the most useful sentence in the report. But an inspector or the investigator's lawyer reads it as an unsupported opinion.

E6(R3) expects investigators to keep oversight of the trial at their site,1 so the concern deserves a fact in its place: the investigator was not available on the visit day, oversight was not discussed, and a call is booked for October 8. That version can be checked, and it produces an action.

The monitoring visit follow-up letter: what goes to the investigator and what stays in the report

In shortSponsors must tell investigators about findings relevant to their work, and they usually do so in a short letter written after the report. It has a different reader, so it carries actions, owners and dates, and leaves out internal classification and escalations. Practice varies: some sponsors send the report itself.

FDA's 2023 guidance puts it in one sentence: "sponsors should inform the clinical investigator of monitoring findings from monitoring activities that are relevant to the clinical investigator's activities."3 E6(R3) adds that important deviations "should be highlighted and should be the focus of remediation efforts as appropriate".1 A letter where the one important item sits fourth in a list of five identical lines has met the first and missed the second.

Neither text requires a letter, and at least one public template has the monitor send the report to both the sponsor and the investigator.20 The split below is common practice among sponsors who keep them separate, and a choice you should write down.

Why the letter comes from the signed report and comes second

A letter sent before the report is reviewed can tell a site one thing that the signed report then changes. FDA's inspectors check whether "monitoring letters/communications given to the sites" met their own timeline.2 So the plan needs a date for the letter too, counted from a known event. One courtesy also has evidential value: naming what the site has closed since the last visit. A letter of complaints alone reads as adversarial, and a site's own file then lacks the record that findings do get fixed.

What FDA, EMA and MHRA inspectors write about monitoring and monitoring reports

In shortEMA's inspectors recorded 35 major monitoring findings in 2024, the third largest group of 335. FDA lists failing to ensure proper monitoring among common sponsor observations, though most of its sponsor inspections end with nothing to act on. The published findings share three shapes: something missed, something left out, and a plan nobody followed.

Something missed, something left out, a plan not followed: what the findings say

In these quotes IMP means investigational medicinal product, the trial medicine. SDV is source data verification, comparing database entries with the clinic's records. IC is informed consent, and PI is the principal investigator.

Monitoring reports also get read when an inspector is looking at a site. An August 2023 warning letter to a clinical investigator records the investigator's written response on one observation: the monitor did not raise it "during the clinical trial or in any of the monitoring reports".

FDA called that response inadequate: "Although the monitor did not bring this observation to your attention during the conduct of the clinical trial, as the clinical investigator, you are ultimately responsible for ensuring compliance with the investigational plan."23 Silence in a monitoring report helped nobody there.

Keep these findings in proportion. The MHRA's seven commercial sponsor inspections in 2019 to 2020 averaged 2.4 major and 4.9 other findings each.4 Findings are normal, and most FDA sponsor inspections end with no action indicated.24 Our own judgment, which no source measures: a warning letter is the rare outcome of a weak report. The likelier cost is a slower inspection with more questions, and a problem found in a report signed months earlier that the sponsor could have acted on then.

Where a CRA's hours go, what risk-based monitoring changed, and the number nobody publishes

In shortThe best-known workload study dates from 2012: 41% of a CRA's time on site, about 22% on off-site monitoring, where report writing sits. No study publishes hours per monitoring report. Newer survey work shows fewer on-site visits and a constant number of sites, and turnover has eased from a high of 30%.

No public figure for hours per monitoring visit report, and how to find yours

You may hear that a report takes two to four hours. We found no study that measures it. The closest statement comes from a vendor, from its own time and motion work: "For every 1,000 trip reports, CRAs spend more than 780 days working in various systems."28 That works out to about 0.78 of a day per report, by our arithmetic, with no sample size and no split between writing and everything else.

It is one vendor's figure, published to sell software, and the only number we can point to. Time ten of your own. Part C shows how.

Fewer site visits make each interim report carry more

The strongest evidence on monitoring itself is a 2021 Cochrane review, a formal summary of eight studies. Its comparison of risk-based with extensive on-site monitoring rests on two large studies. It finds with moderate certainty that risk-based monitoring is not inferior for major or critical findings (risk ratio 1.03, 95% confidence interval 0.81 to 1.33, where 1 would mean no difference). It finds with low certainty that extensive on-site monitoring costs considerably more, up to a factor of 3.4.29 The authors call the evidence base limited. A separate 2024 scoping review of source data verification, which compares database entries with the clinic's records, found no absolute measure of its accuracy at all.30

Practice has moved anyway. Tufts' survey found 47.2% of CRAs reporting fewer on-site visits, and about a quarter of CRA work done remotely.5

The next step is our own reasoning, and no study measures it. If visits drop and sites stay constant, each interim report covers a longer stretch. Open actions wait longer between mentions, and more of what the sponsor knows comes from systems the monitor did not visit. So the report's job of bringing several sources together grows heavier as visits thin out. A monitor whose site moves from the survey's seven-week average to its 12-week low-risk average writes up 12 weeks of accumulated change.

We found no public market size for this work, and no public count of report volumes, of spend on writing them or of sponsors using drafting tools. If someone quotes one, ask for the source. For scale, a 2014 study for the US health department put site monitoring at $1.6 million per Phase 3 study, a line far larger than report writing alone.32

AI in clinical trial monitoring: what FDA and EMA have said about drafting a monitoring report

In shortNo regulator has a rule for or against software that drafts a monitoring report. FDA's draft leaves out AI used for operational efficiency, but only where that use does not affect patient safety or study reliability, and a monitoring report can carry an escalation. So the sponsor should state its reasoning in writing. EMA expects GCP to apply, and the record has to stay attributable to people.

Where a drafting tool sits on FDA's two factors, model influence and decision consequence

FDA's draft frames risk with two factors: how much of the evidence comes from the model, and how serious a wrong decision would be. Apply them to this work. Transcribing a monitor's dictation has low influence, because the monitor confirms it. Writing "no findings requiring escalation" would have high consequence if nobody checked. So influence stays low only while another check stands behind each output: a citation to source, a comparison a person can see, a signature by someone who read it.

The limits of software on a monitoring report, and the evidence so far

Software cannot see what the monitor did not look at. It can compare a sentence with a record, but it cannot know the site's fridge log was in the wrong binder. A fluent draft can also lower a reviewer's guard: a manager who has read 50 clean paragraphs reads the 51st faster. That risk has to be tested, and Part C shows how to plant errors to do it.

The evidence is thin. We found no peer-reviewed study of AI drafting of monitoring visit reports. One sponsored article reports a 90% cut in trip report writing time at one contract research organization, and states no sample, period or baseline.45 Treat it as a claim to test on your own reports. E6(R3) still has the sponsor decide and record, and it holds monitors and other staff to their duties: they "should adhere to data protection and confidentiality requirements".1

How sponsors and CROs write and review monitoring reports today: people, hand-offs and hours

In shortA CRA writes, a trial manager or lead CRA reads and signs, a clinical lead decides what escalates, and quality watches for serious breaches. Most of the wait is for information that already exists somewhere. Teams write in a word processor or a CTMS module, hand the work to a CRO, or use a drafting tool, and each option leaves different work to people.

The CRA, the trial manager and the clinical lead: who touches a report

A word processor, a CTMS, a CRO, a writing assistant or drafting software: five ways to produce the report

A monitoring visit report with a reviewer in the margin: Site 114 from draft to signed letter

In shortThis is the example from the top of the page, inside the product. Lena Ortiz, the clinical trial manager, opens Sam Patel's report on day 4 of 10. The agents wrote it from four sources, and the report reviewer has left five comments in the margin. Three must be fixed before she can sign. She fixes them, signs, and the follow-up letter is written from the signed report.

1

The report, last visit's actions and five comments on one screen

The queue on the left holds 4 reports that need Lena, 2 with notes in and not yet drafted, and 2 with the CRA. The middle is MVR-26-0412, Site 114 Riverside Dermatology Research, interim visit 6 on October 1. Every sentence carries a numbered citation to the notes, the checklist, the last report or the site data.

Above section 01 sit the three actions from the last report, each with its fate. The second is marked in red: not in this report. The banner reads "3 must-fix comments open", and signing stays locked until each is fixed or dismissed with a reason.

2

Why the fridge action matters, with the evidence and a suggested sentence

Lena presses Why on the first comment she cares about: "AI-114-031 from IMV 5, the fridge excursion, is still open. Why isn't it in this report?" The panel on the left opens the last report at that action. It was raised August 27 and due September 15, and it appears in neither the notes nor the draft. The checklist marks previous action items as Partial.

The comment paraphrases the rule that every report follows up actions left unresolved. The real clause is ICH E6(R3) 3.11.4.6(a).1 A suggested sentence is ready, for her to apply or not.

3

One click writes the sentence and carries the action, open 41 days

Apply fix makes two changes. A sentence goes into the investigational product section: the action was not discussed at this visit and remains open after 41 days. The action goes into the action table with a new date, October 9. At the top, AI-114-031 now reads "Carried forward · open 41 d", and the banner drops to two.

The 41 counts from August 27 to the review day, October 7. On the day of the visit it was 35. Section 05 explains why a plan should fix that rule.

4

A reminder becomes an escalation under the monitoring plan

Participant 114-019 signed consent form version 3.0 on September 9, after version 4.0 was approved on August 22 and in use from September 1. Sam's draft says the site was reminded. The sample's monitoring plan, in §7.2, makes this an important protocol deviation to escalate within 2 working days.

The fix rewrites the sentence, fills the findings-requiring-escalation section and adds an action: re-consent 114-019 on version 4.0 by October 14 and file a note with both versions. On the Escalations screen it appears with "Decide by Oct 8". Two working days from the visit ended on October 5, so a real plan must say when that clock starts.

5

"No rescue medication" is corrected against the notes and the EDC

The draft says no rescue or prohibited medication was recorded. Sam's own notes and the EDC both show 114-011 took oral prednisone for 7 days from September 18, prescribed by an outside clinic for a flare. Under the sample's protocol, §6.4, that is rescue therapy.

With this fix the banner changes to "Ready to sign · 2 minor comments left, your call". The report writer drafted that wrong sentence from a paragraph that said the opposite, and the review step caught it. That is why the writer and the reviewer are separate.

6

The action table and the escalation, ready for signature

Section 10 now lists every action with owner, due date and status: one closed, three new, the carried fridge action and the new re-consent. Section 11 states the escalation under the plan.

Section 12 still says site conduct is satisfactory overall. No comment asks about it, and a careful manager would. The tool flags what its rules cover, and judgment on the overall conclusion stays with her.

7

She signs under a stated meaning, with two minor comments left open

The dialog shows 3 of 5 findings resolved, 5 open actions and 1 escalation. It names the signer and the meaning of the signature: "I have reviewed and approve this monitoring report." She enters her password.

In this run the two minor comments stay open and are recorded as accepted as written by her. So the signed report keeps "22 randomized" against 23 in IRT, and the opinion about the investigator. Each was one click from being fixed, and most teams would fix both. A stricter plan can make them must-fix.

8

The follow-up letter is written from the signed report

The letter writer runs only after signature. It thanks Dr. Nora Feld and Jess Moreno, says what was reviewed, lists five actions with owner and due date, names the action closed since last time and gives the next visit, October 29.

The re-consent appears as an action to do. The word "important" and the escalation stay in the report. Lena presses Send follow-up letter, and the report and letter are filed to the trial master file.

9

Every person and agent on one activity trail

The Activity tab lists each step with who and when: Sam dictated, the report writer drafted 12 sections from 4 sources, the reviewer found 5 comments, Sam confirmed, Lena applied three fixes and signed, the letter writer drafted and sent. Agent steps and human decisions are marked apart.

A quality reader can answer "who decided this, and when?" from this one list.

Select any screen to open it larger. Dates and times are shown in US form. Site, person and product names are sample data.

From dictated visit notes to a checked trip report: Omar's visit to Kestrel Heart Institute

In shortA second visit, this time from the start. Omar Haddad dictates 4 minutes 39 seconds of notes on Site 309. Lena presses Write the report. The agents read the sources in turn, the report fills in section by section, and three comments arrive, the first asking why last visit's consent issue is missing.

1

The notes arrive with the checklist, the last report and the site data

Omar visited Kestrel Heart Institute in Denver on October 6: CRV-210, a trial of Dravenzo, interim visit 3. His dictation is transcribed into 6 paragraphs with the facts highlighted, and the sources are named on the page: 8 checklist items, 3 actions to roll forward, and site data from CTMS, EDC and IRT.

2

The agents write the report, section by section

The notes reader finds 6 paragraphs, 9 participants and 34 facts. The checklist matcher matches 8 items and marks 2 as partial or No. The carry-forward tracker finds 2 of the 3 actions still open. The site data check compares enrollment, medications and queries. The report writer then fills 12 sections of the CRV-210 template while the screen follows.

On the sample this takes under a minute. For the Site 114 report the panel shows "Notes to checked draft in 39.6 s".

3

"Why isn't last visit's consent issue mentioned?"

Three comments appear, two of them must-fix. AI-309-007, re-consent participant 309-003 on version 3.1, raised at visit 2 on August 12, is still open after 56 days. The draft says every consent is on the current version. The notes never say whether 309-003 was re-consented, so the sentence cannot stand.

The suggested text says the re-consent was not verified at this visit and carries the action forward. It leaves the question open and says so.

4

An action past the escalation rule, and a log nobody reviewed

The second must-fix: AI-309-008, a sub-investigator's signed CV and GCP certificate. The sample's tracker records it as carried over two visits, which trips the plan's rule, while the draft says "No findings requiring escalation". The third asks about the September pharmacy temperature log, not available at the visit, with no follow-up planned.

These are omissions a re-read would not catch. Each of these two sentences was accurate to the notes.

Every report, its 10-day clock, every open action and every escalation across a monitoring team

In shortBeyond a single report, a trial manager needs four views: all reports by stage, a clock board for each CRA, every action by age, and a list of escalations to decide. A dashboard shows what the reviewer catches. Its numbers here are sample data and design targets to measure in a pilot.

1

All reports, with stage, findings and the report clock

Twelve reports, with filters for those needing Lena, notes in, with the CRA, at risk and signed. Site 121 in Leeds reads day 11 of 10 and overdue: Lena returned it asking Dana Okafor to carry forward an action past the 60-day limit and add the escalation.

2

A clock board for each CRA, from visit day to signature

One row per CRA, one bar per report, colored by who holds it, with planned visits to the right. It shows at a glance that Dana's Site 121 has overrun and that Omar's notes for Site 309 are waiting.

3

Action items aged across sites, so an old one cannot hide

Columns for 0 to 30 days, 31 to 60, over 60 and closed. A nightly action watch moves cards and escalates those past the limit or carried over two visits. Opening one shows its age, visits carried and history, with three choices: remind the site, escalate, or close with evidence.

4

One action, and the only three things you can do with it

AI-114-031 has been open for 41 days, carried over 1 visit, against a threshold of 60. Closing it takes evidence.

5

Escalations to decide, each with its rule, and the decision log

Three to decide: the consent at Site 114, a prohibited medication at Site 314 under a same-day rule, and an action 74 days old at Site 121. Below them, decisions from the last 30 days with who and when. Lena and the clinical lead, Dr. Maya Chen, both decide here.

A decision opens a dialog with choices drawn from the plan, including notifying quality of a possible serious breach, and a comment for the record. The software does not choose.

6

Recording the decision on a consent deviation

Three options, one required, and a comment. The decision goes on the report and the activity trail, which is what E6(R3) 3.11.4.6(c) asks: the sponsor decides, and the decision is recorded.1

What the sample dashboard says the reviewer caught in 30 days

The dashboard shows signed within the clock, visit to signed, CRA writing time and findings fixed before signing. On this sample those values are design targets for a fictional team, with no real customer behind them, so measure them yourself in a pilot. Its most useful panel is the split of what the reviewer raises, because that tells a monitoring lead what to train on.

Report clocks, escalation rules and reviewer checks become settings

The plan's rules live on one screen: working days for the CRA, the manager and the letter; the rules for consent, prohibited or rescue medication, actions open too long and suspected serious breaches; and each reviewer check, on or off. Templates per visit type, the meaning of the signature and the filing location are there too. They take effect on every report.

Notes reader to letter writer: six agents and a site data check, and the people who decide

In shortEach agent has one job and a line it never crosses. A separate agent reviews what the writer wrote. The CRA confirms the draft. The trial manager fixes or dismisses each comment, decides escalations and signs. A person presses Send on the letter.

These six are the solution's named agents. The running screen also shows a seventh step, the site data check, which compares enrollment, medications, deviations and queries with CTMS, EDC and IRT, and never changes those systems.

The CRA confirms, the trial manager signs, the clinical lead decides what escalates

The CRA writes and the manager signs, so the maker and the checker of each report are different people. Signatures record the printed name, the date and time and the meaning, as 21 CFR 11.50 describes.39 Comments cannot close themselves: a dismissal needs a reason.

The four source panels a reviewer can open beside the report

Any citation opens its source beside the sentence. For Site 114, the notes hold the dictation, the checklist shows item 8 as Partial and item 10 as No, the site data shows 23 randomized and 14 open queries, and the agents panel shows how the draft was built.

From dictation, checklist and last report to a signed report, a site letter and tracked actions

In shortFive inputs, five outputs. Your systems of record stay where they are. The solution reads from CTMS, EDC and IRT, works to your template and plan, and files to your trial master file.

Your CTMS, EDC, IRT and eTMF stay as the systems of record

What the solution was designed to reach, and what supports your compliance

These are design targets from the solution's own data. Measure them yourself in a pilot.

What a late monitoring report, a returned draft and a dropped action cost a sponsor

In shortThe cost you can see is your CRAs' hours. The cost you cannot see is what a late or incomplete report delays: an escalation, a correction, a decision on a site. Published figures frame the scale of monitoring and the price of a day. No source publishes the cost of a report, so measure your own, and you can do most of it in a week.

Timing ten reports and reading twenty: finding your own hours and return rate

What a dropped action or a late escalation does that no spreadsheet prices

What monitoring visit report automation returns: CRA hours, shorter reviews and fewer returned drafts

In shortPut in your own numbers. The calculator values CRA hours released from writing, manager hours released from reading, and rework avoided when fewer drafts come back. It leaves inspection outcomes out, because nobody can honestly price them. Every default is an assumption or a sample figure. Replace them.

Writing, review, returns and escalation time: where report automation saves

Reports a year, hours per report and return rate, on your own figures

How ready your monitoring team is: plan rules, template, data access, sign-off and a clock you can defend

In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

Twelve questions for any CTMS or monitoring report software vendor, us included

In shortAlmost any tool writes fluent paragraphs. These questions test what a demonstration hides: whether each sentence can be traced, whether a dropped action will be noticed, who can close what, and what happens to site data. Ask us too.

Testing monitoring report automation in ten weeks: closed visits, planted errors and one live study

In shortStart with visits you have closed, because you know what those reports said. Load your plan and template, write the reports again, compare. Plant errors to see whether the reviewer catches them. Then run one live study beside your usual process, and decide on five numbers.

Planted errors caught, hours and false alarms on your own visit reports

The thresholds are our suggestion. Set yours with your quality group before the pilot starts.

Monitoring visit report questions answered: template, deadline, follow-up letter, deviations and AI

In shortQuestions CRAs, trial managers and buyers search for, each answered on its own.